Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Gilead’s Yeztugo beats forecasts as HIV PrEP franchise exceeds $1B

Gilead said its twice-yearly HIV prevention shot Yeztugo generated $232 million in sales in the second quarter, topping Wall Street estimates of $221 million. The beat comes about three months after Gilead said it expected ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Finance & Markets

More from Wednesday 5 August →